19 May 2020 --- ADM Biopolis and Hospital de Sagunto, in Spain, have launched a clinical trial into the effects of administering a food supplement containing three of ADM’s live probiotic strains on COVID-19 patients. The trial began at the end of March and aims to promote gut microbiome balance to help improve health functions related to outcomes for COVID-19 patients in high-risk groups. Probiotics’ potential in tackling the novel coronavirus is increasingly brought to the fore and many players in the space are exploring this opportunity.
